SEC Form 4 · accession 0001209191-19-005618
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandy Macrae
Officer — President and CEO · Director
Period of report
Jan 24, 2019
Accepted (ET)
Jan 28, 2019 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 24, 2018 | F | 3,974 | $11.10 | D | 27,526 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares underlying the portion of the restricted stock unit grant that vested on January 24, 2019 surrendered by the Reporting Person to the Issuer for tax withholding, using the Issuer's closing stock price on January 24, 2019 of $11.10/share, pursuant to the terms of the Issuer's 2013 Stock Incentive Plan.
- F2Includes 6,526 shares resulting from the January 24, 2019 vesting of Reporting Person's January 24, 2018 restricted stock unit grant and 21,000 shares subject to such restricted stock unit grant that will vest in two (2) additional equal annual installments on each anniversary of the grant date, such that they will be vested in full on the third (3rd) anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer through such date.